Patrick Forde (@FordePatrick) / X

Patrick Forde

3,571 posts

Patrick Forde

@FordePatrick

Lung cancer & Mesothelioma. Immunotherapy believer.

scholar.google.com/citations?hl=e…

Joined June 2019

Pinned
Patrick Forde
@FordePatrick
Jun 3, 2025
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/
42K
Patrick Forde
@FordePatrick
Apr 10, 2021
Today at #AACR21 I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who made it possible. In this thread I will discuss why we did the study, results and next steps/
Patrick Forde
@FordePatrick
Apr 13, 2022
Patient-centered summary of the #CheckMate816 neoadjuvant chemo-immunotherapy clinical trial. This is a new treatment for patients with stage 1-3 non-small-cell lung cancer that can be removed by surgery. The summary may be useful for clinicians & patients. #lcsm @LUNGevity
Patrick Forde
@FordePatrick
Mar 4, 2022
Chemo-immunotherapy for earlier stage lung cancer approved! 8yrs have flown since our 1st trial of neoadj nivo began, thanks to many incl @SU2C @AACR @bmsnews @LUNGevity Most of all pts with a leap of faith to take part in cancer trials, this is for you!
news.bms.com
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant...
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1 In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy...
Patrick Forde
@FordePatrick
Apr 11, 2022
Today, CheckMate 816, a phase 3 trial of neoadjuvant chemo + nivolumab immunotherapy was published i - this was a global effort to improve the lives of pts dealing with newly diagnosed surgical lung cancer. nejm.org/doi/full/10.10…
Patrick Forde
@FordePatrick
Jun 2, 2024
Anyone still think we should not be using immune checkpoint inhibitors before surgery? Or that use of adjuvant ICI only is as good as neoadjuvant ICI? Phase 3 trial in resectable melanoma now in @NEJM concurrent with plenary by @ProfCUBlankNKI #ASCO24 nejm.org/doi/full/10.10…
38K
Patrick Forde
@FordePatrick
Sep 8, 2024
With the goal of addressing a key clinical question, which pts w lung cancer may benefit from adjuvant immunotherapy after neoadjuvant, today at #WCLC2024 we presented results of an exploratory individual pt level analysis of the #CM77T & #CM816 trials 1/
42K
Patrick Forde
@FordePatrick
Jun 2, 2024
Impressive increase in PFS with consolidation osimertinib after CRT for pts w unresectable stage III lung cancer. Crossover on progression 82% higher than in most other studies. OS far from mature. Will be adopted as a new standard where it is available I believe. #lcsm #ASCO24
31K
Patrick Forde
@FordePatrick
Jun 4, 2024
Initial thoughts I will bring back to clinic from LAURA and ADRIATIC from #ASCO24 #lcsm
21K
Patrick Forde
@FordePatrick
Nov 8, 2021
Delighted to see 7 yrs of work on chemo-immunotherapy for #mesothelioma come to fruition today in @NatureMedicine ! Developed within @eaonc @PrECOGonc PrE0505 was a investigator-initiated collaboration across 15 academic and community cancer centers. 1/
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and...
From nature.com
Patrick Forde
@FordePatrick
Oct 5, 2022
Lung cancer in the 2020s is the breast cancer of the 1990s and 2000s?
Patrick Forde
@FordePatrick
Jun 2, 2024
The new standard of care is consolidation immunotherapy for limited stage small cell lung cancer & the first systemic therapy advance for limited small cell in ~50yrs. Allied to Laura we had fun on the @ASCO non-metastatic NSCLC/SCLC/meso track committee this year! #lcsm #ASCO24
11K
Patrick Forde
@FordePatrick
Jun 22, 2024
Out now in @JTOonline consensus recommendations from @IASLC on use of neoadjuvant and adjuvant therapy for lung cancer. #lcsm jto.org/article/S1556-…
16K
Patrick Forde
@FordePatrick
Aug 20, 2025
Published in today’s print edition of @NEJM the final survival results of neoadjuvant nivo in lung cancer along with a 2 min quick take video & an elegant editorial from Dr. @VirginiaCalvo6 ! #LCSM @gecp_org nejm.org/do/10.1056/NEJ…
11K